GLAXOSMITHKLINE PHARMA LT (GLAXO) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↑

+0.44%

Short-term demand accumulation with positive intraday momentum.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 4.8%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 45.6%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹2,626.73

200-Day DMA ● Overlay

₹2,436.19

14-Day RSI ● Overlay

53.5 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹46,944 Cr

Large cap

Stock P/E (TTM) Valuation

44.6x

Price / EPS

Book Value (₹) Assets

₹134.0

P/B: 20.6x

ROE (%) Quality

45.6%

Net Profit / Equity

ROCE (%) Efficiency

61.4%

EBIT / Capital

Dividend Yield Yield

2.06%

Face Value: ₹10

Debt / Equity Solvency

0.01x

Low Debt

EPS (TTM) Per Share

₹61.88

Trailing 12M

OPM (%) Spread

34.0%

EBITDA Margin

Free Cash Flow Cash

₹870.00 Cr

CFO - Capex

About GLAXOSMITHKLINE PHARMA LT

GLAXOSMITHKLINE PHARMA LT (GLAXO) is an Indian publicly traded enterprise listed on the National Stock Exchange (NSE).

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 24.5% × Turnover: 0.85x × Leverage: 1.01x = ROE: 45.6%

✓ Company Strengths (Pros)

• Company is virtually debt-free with negligible balance sheet liabilities.
• Company has a stellar track record of return on equity (ROE of 45.6%).

⚠ Key Considerations & Risks (Cons)

• Stock is trading at a premium of 20.6x its book value.

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹3,955 Cr

Latest PAT

₹1,068 Cr

EPS (TTM)

₹61.88

OPM %

34.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹762.00 Cr	₹957.00 Cr	₹805.00 Cr	₹930.00 Cr	₹815.00 Cr	₹1,011 Cr	₹949.00 Cr	₹974.00 Cr	₹805.00 Cr	₹980.00 Cr	₹1,041 Cr	₹995.00 Cr	₹938.00 Cr
Operating Profit (EBITDA)	₹144.00 Cr	₹289.00 Cr	₹218.00 Cr	₹257.00 Cr	₹231.00 Cr	₹322.00 Cr	₹292.00 Cr	₹333.00 Cr	₹251.00 Cr	₹336.00 Cr	₹371.00 Cr	₹351.00 Cr	₹296.00 Cr
OPM %	19.0%	30.0%	27.0%	28.0%	28.0%	32.0%	31.0%	34.0%	31.0%	34.0%	36.0%	35.0%	31.0%
Interest Expense	₹0 Cr	₹0 Cr	₹0 Cr	₹1.00 Cr	₹0 Cr	₹0 Cr	₹0 Cr	₹1.00 Cr	₹0 Cr	₹1.00 Cr	₹1.00 Cr	₹1.00 Cr	₹1.00 Cr
Depreciation	₹16.00 Cr	₹18.00 Cr	₹17.00 Cr	₹18.00 Cr	₹16.00 Cr	₹17.00 Cr	₹19.00 Cr	₹15.00 Cr	₹16.00 Cr	₹17.00 Cr	₹20.00 Cr	₹13.00 Cr	₹16.00 Cr
Profit before Tax (PBT)	₹181.00 Cr	₹299.00 Cr	₹65.00 Cr	₹271.00 Cr	₹249.00 Cr	₹344.00 Cr	₹308.00 Cr	₹359.00 Cr	₹279.00 Cr	₹354.00 Cr	₹400.00 Cr	₹373.00 Cr	₹322.00 Cr
Net Profit (PAT)	₹132.00 Cr	₹218.00 Cr	₹46.00 Cr	₹194.00 Cr	₹182.00 Cr	₹252.00 Cr	₹230.00 Cr	₹263.00 Cr	₹205.00 Cr	₹257.00 Cr	₹296.00 Cr	₹278.00 Cr	₹237.00 Cr
EPS in ₹	₹7.81	₹12.84	₹2.70	₹11.48	₹10.76	₹14.91	₹13.57	₹15.52	₹12.10	₹15.20	₹17.45	₹16.40	₹14.00

Annual P&L (₹ Cr)	Mar 2015 15m	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	₹3,305 Cr	₹2,838 Cr	₹2,908 Cr	₹2,871 Cr	₹3,128 Cr	₹3,224 Cr	₹2,926 Cr	₹3,278 Cr	₹3,252 Cr	₹3,454 Cr	₹3,749 Cr	₹3,822 Cr	₹3,955 Cr
Expenses	₹2,672 Cr	₹2,360 Cr	₹2,489 Cr	₹2,363 Cr	₹2,527 Cr	₹2,567 Cr	₹2,327 Cr	₹2,516 Cr	₹2,447 Cr	₹2,545 Cr	₹2,570 Cr	₹2,512 Cr	₹2,601 Cr
Operating Profit	₹633.00 Cr	₹478.00 Cr	₹420.00 Cr	₹508.00 Cr	₹601.00 Cr	₹657.00 Cr	₹598.00 Cr	₹762.00 Cr	₹804.00 Cr	₹909.00 Cr	₹1,179 Cr	₹1,309 Cr	₹1,354 Cr
OPM %	19%	17%	14%	18%	19%	20%	20%	23%	25%	26%	31%	34%	34%
Interest	₹0 Cr	₹0 Cr	₹0 Cr	₹0 Cr	₹1.00 Cr	₹6.00 Cr	₹4.00 Cr	₹2.00 Cr	₹2.00 Cr	₹2.00 Cr	₹1.00 Cr	₹3.00 Cr	₹3.00 Cr
Depreciation	₹25.00 Cr	₹25.00 Cr	₹27.00 Cr	₹38.00 Cr	₹49.00 Cr	₹83.00 Cr	₹79.00 Cr	₹68.00 Cr	₹66.00 Cr	₹70.00 Cr	₹67.00 Cr	₹66.00 Cr	₹67.00 Cr
Profit before Tax	₹756.00 Cr	₹578.00 Cr	₹511.00 Cr	₹540.00 Cr	₹683.00 Cr	₹306.00 Cr	₹525.00 Cr	₹2,093 Cr	₹839.00 Cr	₹816.00 Cr	₹1,260 Cr	₹1,406 Cr	₹1,449 Cr
Net Profit	₹476.00 Cr	₹376.00 Cr	₹337.00 Cr	₹351.00 Cr	₹445.00 Cr	₹93.00 Cr	₹358.00 Cr	₹1,695 Cr	₹611.00 Cr	₹590.00 Cr	₹928.00 Cr	₹1,036 Cr	₹1,068 Cr
EPS in Rs	28.12	22.20	19.88	20.70	26.29	5.50	21.14	100.04	36.05	34.83	54.75	61.15	63.05

Balance Sheet (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	₹85.00 Cr	₹85.00 Cr	₹85.00 Cr	₹85.00 Cr	₹169.00 Cr	₹169.00 Cr	₹169.00 Cr	₹169.00 Cr	₹169.00 Cr	₹169.00 Cr	₹169.00 Cr	₹169.00 Cr
Reserves & Surplus	₹1,744 Cr	₹2,099 Cr	₹1,922 Cr	₹1,973 Cr	₹1,970 Cr	₹1,651 Cr	₹1,309 Cr	₹2,494 Cr	₹1,572 Cr	₹1,608 Cr	₹1,782 Cr	₹2,098 Cr
Borrowings (Debt)	₹3.00 Cr	₹2.00 Cr	₹2.00 Cr	₹1.00 Cr	₹1.00 Cr	₹0 Cr	₹35.00 Cr	₹20.00 Cr	₹16.00 Cr	₹19.00 Cr	₹10.00 Cr	₹33.00 Cr
Total Liabilities	₹3,216 Cr	₹3,055 Cr	₹3,004 Cr	₹3,947 Cr	₹3,911 Cr	₹3,136 Cr	₹3,115 Cr	₹4,633 Cr	₹3,327 Cr	₹3,557 Cr	₹4,108 Cr	₹4,324 Cr
Fixed Assets	₹123.00 Cr	₹204.00 Cr	₹258.00 Cr	₹325.00 Cr	₹432.00 Cr	₹758.00 Cr	₹387.00 Cr	₹331.00 Cr	₹330.00 Cr	₹321.00 Cr	₹284.00 Cr	₹281.00 Cr
Total Assets	₹3,216 Cr	₹3,055 Cr	₹3,004 Cr	₹3,947 Cr	₹3,911 Cr	₹3,136 Cr	₹3,115 Cr	₹4,633 Cr	₹3,327 Cr	₹3,557 Cr	₹4,108 Cr	₹4,324 Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operations (CFO)	₹338.00 Cr	₹139.00 Cr	₹234.00 Cr	₹473.00 Cr	₹409.00 Cr	₹490.00 Cr	₹578.00 Cr	₹811.00 Cr	₹484.00 Cr	₹582.00 Cr	₹1,290 Cr	₹903.00 Cr
Cash from Investing (CFI)	₹180.00 Cr	₹499.00 Cr	₹301.00 Cr	-₹104.00 Cr	-₹153.00 Cr	-₹57.00 Cr	₹418.00 Cr	-₹406.00 Cr	₹808.00 Cr	₹9.00 Cr	-₹46.00 Cr	₹397.00 Cr
Cash from Financing (CFF)	-₹497.00 Cr	-₹638.00 Cr	-₹511.00 Cr	-₹307.00 Cr	-₹358.00 Cr	-₹428.00 Cr	-₹696.00 Cr	-₹524.00 Cr	-₹1,543 Cr	-₹562.00 Cr	-₹769.00 Cr	-₹737.00 Cr
Free Cash Flow (FCF)	₹175.00 Cr	-₹69.00 Cr	-₹24.00 Cr	₹639.00 Cr	₹166.00 Cr	₹336.00 Cr	₹536.00 Cr	₹2,371 Cr	₹451.00 Cr	₹573.00 Cr	₹1,273 Cr	₹870.00 Cr

Efficiency Ratios	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days (DSO)	11	16	21	19	14	11	27	23	22	23	28	26
Inventory Days	91	156	111	147	131	135	159	144	131	144	126	124
Cash Conversion Cycle (Days)	27	75	60	17	36	46	50	11	31	-4	-31	-4
ROCE %	42%	29%	22%	26%	31%	33%	38%	37%	36%	51%	63%	61%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹945.08 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹2,722.00

DCF Fair Value

₹945.08

Graham Number

₹431.94

Margin of Safety

-73.8%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹945.08

Premium / Overvalued (Margin: -73.8%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹920	₹911	₹903	₹895
10%	₹937	₹928	₹920	₹912
12%	₹954	₹945	₹937	₹928
14%	₹971	₹962	₹953	₹945

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹945	Fairly Valued
Benjamin Graham Number	₹432	Market Priced
Historical Sector P/E	₹1,361	Premium
EV / EBITDA Multiplier	₹2,858	In-Line
Free Cash Flow Yield Model	₹2,668	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 9/9 (Strong Financial Health)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

9 / 9 Pass

Altman Z-Score

6.31 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Debt/Equity: 0.01x (Safe)

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Positive Operating & Free Cash Flow

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 34.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

75.00%

FIIs (Foreign)

4.79%

DIIs (Domestic)

7.81%

Government

0.15%

Public / Retail

12.42%

Swipe → to view historical quarters

Category	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
+ Promoters	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%
+ FIIs (Foreign Portfolio)	2.50%	2.93%	3.48%	4.02%	4.36%	4.50%	4.52%	4.89%	4.79%	4.63%	4.62%	4.79%
+ DIIs (Mutual Funds / Insurance)	10.01%	8.64%	7.90%	7.51%	7.34%	7.30%	7.79%	7.71%	7.75%	7.70%	7.68%	7.81%
+ Public (Retail & HNIs)	12.48%	13.42%	13.62%	13.48%	13.30%	13.21%	12.69%	12.41%	12.45%	12.67%	12.69%	12.42%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

GLAXO Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

GLAXO Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

GLAXO Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹3,484.16

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹3,048.64

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 45x P/E.

🐻 Bear Case (15%) -12.0%

₹2,395.36

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 19:58 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ GLAXOSMITHKLINE PHARMA LT (GLAXO)	Target Stock	₹2,722.00	+0.44%	44.6x	45.6%	61.4%	0.01	₹46,944 Cr
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Specialty Pharma & Generics	₹1,902.30	-0.12%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Divis Laboratories Ltd (DIVISLAB)	API & Custom Synthesis	₹11,367.00	-1.72%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Torrent Pharmaceuticals Ltd (TORNTPHARM)	Sector Peer	₹4,761.00	-0.40%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Hospital Chains & Apollo 24/7	₹8,604.00	+0.64%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
LAURUS LABS Ltd (LAURUSLABS)	Healthcare & Pharma Operations	₹2,429.00	-1.02%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Cipla Ltd (CIPLA)	Respiratory & Generic Medicine	₹1,419.90	+1.15%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	19:58:33 IST	✓ Live Sync
Financial Statements (10Y)	GLAXOSMITHKLINE PHARMA LT Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

GLAXOSMITHKLINE PHARMA LT

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About GLAXOSMITHKLINE PHARMA LT

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title